文献速递心律失常心力衰竭与心肌病

PKP2相关致心律失常性右心室心肌病亲属的家庭筛查

Family Screening in Relatives at Risk for Plakophilin-2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy.
PubMed 文献 · Circulation · 2025-06-17

该研究纳入295名携带致病或可能致病PKP2变异的亲属,中位随访8.5年,发现室性心律失常仅发生于已确诊ARVC的亲属;基于年龄、症状和基线表型识别出3种风险特征并推导出PKP2特异性纵向筛查方案。

要点

  • 室性心律失常仅见于既往已满足ARVC确诊标准的亲属。
  • 临界ARVC亲属进展至确诊的速度是基因阳性/表型阴性亲属的5倍。
  • 20-40岁亲属发生确诊ARVC的风险较≥40岁者增高(HR 2.23,P=0.012)。

核心结论

  • 整合年龄、症状和基线临床表型的循证纵向筛查算法可改善患者管理并提高临床资源分配效率。

研究设计与样本

  • 研究纳入295名携带致病或可能致病PKP2变异的亲属(41%男性;年龄30.9岁[18.0-47.7岁]),来自145个家庭。
  • 表型通过心电图、动态心电图监测和心脏影像学评估,并按2010年任务 force 标准分类。
  • 室性心律失常定义为心脏骤停或猝死、自发性持续性室性心动过速、心室颤动或适当的植入式心律转复除颤器干预的复合终点。
  • 采用Cox回归确定ARVC发生的预测因素,多状态模型评估ARVC发生和室性心律失常出现的概率。

主要发现

  • 基线时110名亲属(37%)患有确诊ARVC。
  • 在8.5年(4.2-12.9年)随访期间,185名基线无确诊ARVC的亲属中62名(34%)进展为确诊ARVC诊断,全部295名亲属中35名(12%)发生室性心律失常。
  • 室性心律失常仅发生于既往已满足确诊ARVC诊断的亲属。
  • 临界ARVC(满足一项次要标准加主要家族史标准)亲属在多状态模型中进展至确诊ARVC诊断的速度是基因阳性/表型阴性(G+/P-)亲属(即仅有主要家族史标准)的5倍。
  • 与≥40岁者相比,20至40岁亲属发生确诊ARVC的风险增加(风险比2.23;P=0.012)。

关键数值与推荐

  • 临界ARVC亲属:每年心电图和动态心电图监测;每2年完整评估(即心电图、动态心电图监测和影像学)。
  • 年轻(<40岁)或有症状的G+/P-亲属:每2年心电图和动态心电图监测;每4年完整评估。
  • 年长(≥40岁)且无症状的G+/P-亲属:每5年完整评估。

临床怎么用

  • 对携带致病或可能致病PKP2变异的亲属,应根据年龄、症状和基线表型进行风险分层并采用相应的纵向筛查方案。
  • 筛查中应重视心电图作为新满足任务 force 标准的最常见首要检查,并结合动态心电图监测和心脏影像学。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Penetrance and risk of ventricular arrhythmias (VAs) in arrhythmogenic right ventricular cardiomyopathy (ARVC) are increasingly recognized as being genotype specific. Therefore, genotype-informed family screening protocols may lead to safer and more personalized recommendations than the current one-size-fits-all screening recommendations. We aimed to develop a safe, evidence-based plakophilin-2 (PKP2)-specific longitudinal screening algorithm. METHODS: We included 295 relatives (41% male; age 30.9 years [18.0-47.7 years]) with a pathogenic or likely pathogenic PKP2 variant from 145 families. Phenotype was ascertained with ECG, Holter monitoring, and cardiac imaging and classified by the 2010 Task Force Criteria. VA was defined as a composite of sudden cardiac arrest or death, spontaneous sustained ventricular tachycardia, ventricular fibrillation, or appropriate implantable cardioverter defibrillator intervention. We performed Cox regression to determine predictors of ARVC development and multistate modeling to assess the probability of ARVC development and occurrence of VA. RESULTS: At baseline, 110 relatives (37%) had definite ARVC. During 8.5 years (4.2-12.9 years) of follow-up, 62 of 185 relatives (34%) without definite ARVC at baseline progressed to definite ARVC diagnosis, and 35 of 295 of all relatives (12%) had VA. VAs occurred only in relatives who previously fulfilled definite ARVC diagnosis. Relatives with borderline ARVC (fulfillment of one minor criterion plus the major family history criterion) progressed 5 times faster in the multistate model to definite ARVC diagnosis and compared with genotype-positive/phenotype-negative (G+/P-) relatives (ie, major family history criterion alone). Relatives 20 to 40 years of age had increased risk for developing definite ARVC (hazard ratio, 2.23; P=0.012) compared with those ≥40 years of age. New Task Force Criteria fulfillment most commonly occurred first on ECGs, followed by Holter monitoring and cardiac imaging. Consequently, 3 risk profiles were identified, and appropriate screening protocols were derived: relatives with borderline ARVC (annual ECG and Holter monitoring; complete evaluation [ie, ECGs, Holter monitoring, and imaging] every 2 years), younger (<40 years of age) or symptomatic G+/P- relatives (every 2 years an ECG and Holter monitoring; complete evaluation every 4 years), and older (≥40 years of age) and asymptomatic G+/P- relatives (complete evaluation every 5 years). CONCLUSIONS: An evidence-based longitudinal screening algorithm that integrates age, symptoms, and baseline clinical phenotype may improve patient care and improve efficiency of clinical resource allocation.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Muller SA, Asatryan B, Gasperetti A, et al. Family Screening in Relatives at Risk for Plakophilin-2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation. 2025. PMID: 40525281. doi:10.1161/CIRCULATIONAHA.125.074058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。